e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Quality management for lung cancer patients
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Time trends in treatment and survival of non-small cell lung cancer in The Netherlands
M. A. van der Drift, H. E. Karim-Kos, S. Siesling, H. J. M. Groen, E. de Vries, M. L. G. Janssen-Heijnen (Nijmegen, Rotterdam, Enschede, Groningen, Eindhoven, Netherlands)
Source:
Annual Congress 2010 - Quality management for lung cancer patients
Session:
Quality management for lung cancer patients
Session type:
E-Communication Session
Number:
286
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. A. van der Drift, H. E. Karim-Kos, S. Siesling, H. J. M. Groen, E. de Vries, M. L. G. Janssen-Heijnen (Nijmegen, Rotterdam, Enschede, Groningen, Eindhoven, Netherlands). Time trends in treatment and survival of non-small cell lung cancer in The Netherlands. Eur Respir J 2010; 36: Suppl. 54, 286
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Does long treatment delay affect survival in metastatic non-small cell lung cancer
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021
Advanced non-small cell lung cancer (NSCLC): observation of chemotherapy in 5 European countries
Source: Annual Congress 2007 - Therapy of lung cancer
Year: 2007
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
Epidemiological and clinical predictors of survival during the first year of the treatment in non-small cell lung cancer patients
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Surveillance imaging and recurrence rates following surgery for non-small cell lung cancer (NSCLC).
Source: Virtual Congress 2020 – Localised non-small cell lung cancer
Year: 2020
Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series
Year: 2010
Delays in the diagnosis and treatment of non-small cell lung cancer
Source: Annual Congress 2010 - Quality management for lung cancer patients
Year: 2010
10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient
Source: Eur Respir J 2015; 46: 280-282
Year: 2015
Our experience with crizotinib in the treatment of non-small cell lung cancer
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Second line therapy for advanced non-small cell lung cancer
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007
Tumour metabolic-flow difference as a potential predictor of survival in non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Staging of lung cancer
Year: 2010
Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002
One year survival differences of EGFR- and KRAS-mutated advanced non-small cell lung cancer (NSCLC) compared to the wildtype population
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Impacts of multi and specific co-morbidities on the survival of non-surgical non-small cell lung cancer
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Survival impact of surgery in the treatment of stage IIIB-IVA non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
Effect of comorbidity on the prognosis of non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 385s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept